10,000 stroke patients to test Real-World power of Clot-Busting drug tenecteplase
NCT ID NCT07271342
First seen Jan 05, 2026 · Last updated May 22, 2026 · Updated 24 times
Summary
This study will follow about 10,000 adults in China who receive the clot-dissolving drug tenecteplase for a stroke. Researchers want to see how well patients recover and if there are any safety issues in real hospital settings, not just controlled trials. The goal is to improve stroke care across the country.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STROKE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Tiantan Hospital, Capital Medical University
RECRUITINGBeijing, 100070, China
Conditions
Explore the condition pages connected to this study.